{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:09:46Z","timestamp":1757452186182,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J3-6788","P3-0296"],"award-info":[{"award-number":["J3-6788","P3-0296"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3270-y","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T10:47:46Z","timestamp":1533293266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Doxycycline-induced photosensitivity in patients treated for erythema migrans"],"prefix":"10.1186","volume":"18","author":[{"given":"Ma\u0161a","family":"Velu\u0161\u010dek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fajko F.","family":"Bajrovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franc","family":"Strle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da\u0161a","family":"Stupica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"3270_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","volume":"379","author":"G Stanek","year":"2012","unstructured":"Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461\u201373.","journal-title":"Lancet"},{"key":"3270_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MC, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic Anaplasmosis, and Babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089\u2013134.","journal-title":"Clin Infect Dis"},{"key":"3270_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/AAC.39.3.661","volume":"39","author":"SW Luger","year":"1995","unstructured":"Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995;39:661\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3270_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/0003-4819-117-4-273","volume":"17","author":"RB Nadelman","year":"1992","unstructured":"Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;17:273\u201380.","journal-title":"Ann Intern Med"},{"key":"3270_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","volume":"138","author":"GP Wormser","year":"2003","unstructured":"Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med. 2003;138:697\u2013704.","journal-title":"Ann Intern Med"},{"key":"3270_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJM199707313370501","volume":"37","author":"RJ Dattwyler","year":"1997","unstructured":"Dattwyler RJ. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997;37:289\u201394.","journal-title":"N Engl J Med"},{"key":"3270_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/0140-6736(90)93103-V","volume":"336","author":"RJ Dattwyler","year":"1990","unstructured":"Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336:1404\u20136.","journal-title":"Lancet"},{"key":"3270_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/0002-9343(92)90270-L","volume":"92","author":"EM Massarotti","year":"1992","unstructured":"Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med. 1992;92:396\u2013403.","journal-title":"Am J Med"},{"key":"3270_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.amjmed.2009.05.011","volume":"123","author":"D Cerar","year":"2010","unstructured":"Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med. 2010;123:79\u201386.","journal-title":"Am J Med"},{"key":"3270_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s150100050069","volume":"28","author":"B Barsic","year":"2000","unstructured":"Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection. 2000;28:153\u20136.","journal-title":"Infection"},{"key":"3270_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF01780661","volume":"24","author":"F Strle","year":"1996","unstructured":"Strle F, Maraspin V, Lotri\u010d-Furlan S, Ruzi\u0107-Sablji\u0107 E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia positive erythema Migrans. Infection. 1996;24:64\u20138.","journal-title":"Infection"},{"key":"3270_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01710737","volume":"21","author":"F Strle","year":"1993","unstructured":"Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993;21:83\u20138.","journal-title":"Infection"},{"key":"3270_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/jac\/30.4.543","volume":"30","author":"F Strle","year":"1992","unstructured":"Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother. 1992;30:543\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"3270_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/cid\/cis402","volume":"55","author":"D Stupica","year":"2012","unstructured":"Stupica D, Lusa L, Ru\u017ei\u0107-Sablji\u0107 E, Cerar T, Strle F. Treatment of erythema Migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55:343\u201350.","journal-title":"Clin Infect Dis"},{"key":"3270_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000458761","volume":"30","author":"S Goetze","year":"2017","unstructured":"Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017;30:76\u201380.","journal-title":"Skin Pharmacol Physiol"},{"key":"3270_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","volume":"17","author":"G Stanek","year":"2011","unstructured":"Stanek G, Fingerle V, Hunfeld K-P, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17:69\u201379.","journal-title":"Clin Microbiol Infect"},{"key":"3270_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2133.1994.tb02933.x","volume":"130","author":"M Bjellerup","year":"1994","unstructured":"Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers , using an objective method for recording erythema. Br J Dermatol. 1994;130:356\u201360.","journal-title":"Br J Dermatol"},{"key":"3270_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1365-2230.1993.tb02242.x","volume":"18","author":"AM Layton","year":"1993","unstructured":"Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline \u2500 a dose-related phenomenon. Clin Exp Dermatol. 1993;18:425\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"3270_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","volume":"5","author":"ER Gomes","year":"2005","unstructured":"Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5:309\u201316.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"3270_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/cid\/cis457","volume":"55","author":"SB Doernberg","year":"2012","unstructured":"Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012;55:615\u201320.","journal-title":"Clin Infect Dis"},{"key":"3270_CR21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1365-2133.2012.10845.x","volume":"166","author":"B Lebrun-Vignes","year":"2012","unstructured":"Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. French network of regional centers of Pharmacovigilance. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012;166:1333\u201341.","journal-title":"Br J Dermatol"},{"key":"3270_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40409-016-0077-4","volume":"22","author":"SV de Oliveira","year":"2016","unstructured":"de Oliveira SV, Guimar\u00e3es JN, Reckziegel GC, Neves BM, Ara\u00fajo-Vilges KM, Fonseca LX, et al. An update on the epidemiological situation of spotted fever in Brazil. J Venom Anim Toxins Incl Trop Dis. 2016;22:22. Available at: \n                    https:\/\/doi.org\/10.1186\/s40409-016-0077-4","journal-title":"J Venom Anim Toxins Incl Trop Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3270-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T18:42:28Z","timestamp":1569091348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3270"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3270-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All three studies from which information on doxycycline adverse events was obtained had been approved by the Medical Ethics Committee of the Ministry of Health of the Republic of Slovenia (No. 38\/05\/06, 36\/05\/09, and 83\/05\/10); two of the studies were registered at\n            \n            , Identifiers NCT00910715 and NCT01163994. All participants gave informed consent in written form prior to participation in the studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Franc Strle is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis\/ESGBOR. All the other authors report no potential conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"365"}}